• Explore /
  • Poster
  • / Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study.

Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study.

Abstract Poster

Authors

null

Heinz-Josef Lenz

USC Norris Comprehensive Cancer Center, Los Angeles, CA

Heinz-Josef Lenz , Josep Tabernero , Takayuki Yoshino , Sara Lonardi , Alfredo Falcone , María Luisa Limón Mirón , Mark P. Saunders , Alberto F. Sobrero , Young Suk Park , Reyes Ferreiro Monteagudo , Yong Sang Hong , Jiri Tomasek , Hiroya Taniguchi , Fortunato Ciardiello , Mouna Sassi , Barbara Peil , Claudia Hastedt , Matus Studeny , Eric Van Cutsem

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02149108

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 671)

DOI

10.1200/JCO.2017.35.4_suppl.671

Abstract #

671

Poster Bd #

H1

Abstract Disclosures

Similar Posters

First Author: Heinz-Josef Lenz

First Author: Heinz-Josef Lenz

First Author: Robert J. Mayer

First Author: Sebastian Stintzing